Human rotavirus vaccine strains and diagnostics

An immunogenic composition comprising:

• a live, attenuated human rotavirus or an inactivated human rotavirus, and an adjuvant that increases immunogenicity of the live, attenuated human rotavirus or inactivated human rotavirus, wherein said live, attenuated human rotavirus or inactivated human rotavirus comprises a NSP1, NSP2, NSP3, NSP4, NSP5, VP1, VP2, VP3, VP4, VP5, VP6 and VP7 protein, and wherein:
• a) the NSP1 protein has greater than 95% identity to SEQ ID NO:
• 2 or SEQ ID NO:
• 3;
• the NSP2 protein has greater than 95% identity to SEQ ID NO:
• 5;
• the NSP3 protein has greater than 95% identity to SEQ ID NO:
• 8;
• the NSP4 protein has greater than 95% identity to SEQ ID NO:
• 11;
• the NSP5 protein has greater than 95% identity to SEQ ID NO:
• 14 or SEQ ID NO:
• 15;
• the VP1 protein has greater than 95% identity to SEQ ID NO:
• 17;
• the VP2 protein has greater than 95% identity to SEQ ID NO:
• 20;
• the VP3 protein has greater than 95% identity to SEQ ID NO:
• 23;
• the VP4 protein has greater than 95% identity to SEQ ID NO:
• 26 or SEQ ID NO:
• 27;
• the VP6 protein has greater than 95% identity to SEQ ID NO:
• 29 or SEQ ID NO:
• 30;
• and
• the VP7 protein has greater than 95% identity to SEQ ID NO:
• 32;
• or
• b) the NSP1 protein has greater than 95% identity to SEQ ID NO:
• 71;
• the NSP2 protein has greater than 95% identity to SEQ ID NO:
• 77 or SEQ ID NO:
• 78;
• the NSP3 protein has greater than 95% identity to SEQ ID NO:
• 83;
• the NSP4 protein has greater than 95% identity to SEQ ID NO:
• 89;
• a NSP5 protein has greater than 95% identity to SEQ ID NO:
• 95 or SEQ ID NO:
• 96;
• the VP1 protein has greater than 95% identity to SEQ ID NO:
• 101 or SEQ ID NO:
• 102;
• the VP2 protein has greater than 95% identity to SEQ ID NO:
• 107;
• the VP3 protein has greater than 95% identity to SEQ ID NO:
• 113 or SEQ ID NO:
• 114;
• the VP4 protein has greater than 95% identity to SEQ ID NO:
• 119 or SEQ ID NO:
• 120;
• the VP6 protein has greater than 95% identity to SEQ ID NO:
• 125;
• and
• the VP7 protein has greater than 95% identity to SEQ ID NO:
• 131,
• wherein the immunogenic composition is formulated for intradermal or intramuscular administration to a subject.

An immunogenic composition comprising a live, attenuated human rotavirus or an inactivated human rotavirus, wherein said live, attenuated human rotavirus or inactivated human rotavirus comprises a NSP1, NSP2, NSP3, NSP4, NSP5, VP1, VP2, VP3, VP4, VP5, VP6 and VP7 protein, wherein the immunogenic composition is formulated for intradermal or intramuscular administration to a subject, and wherein:

• a) the NSP1 protein has greater than 95% identity to SEQ ID NO:
• 3, and wherein amino acid 122 is an arginine;
• the NSP2 protein has greater than 95% identity to SEQ ID NO:
• 5;
• the NSP3 protein has greater than 95% identity to SEQ ID NO:
• 8;
• the NSP4 protein has greater than 95% identity to SEQ ID NO:
• 11;
• the NSP5 protein has greater than 95% identity to SEQ ID NO:
• 15, and wherein amino acid 45 is an isoleucine;
• the VP1 protein has greater than 95% identity to SEQ ID NO:
• 17;
• the VP2 protein has with greater than 95% identity to SEQ ID NO:
• 20;
• the VP3 protein has greater than 95% identity to SEQ ID NO:
• 23;
• the VP4 protein has greater than 95% identity to SEQ ID NO:
• 27, and wherein amino acid 51 is a aspartic acid, amino acid 331 is an phenylalanine, amino acid 364 is an isoleucine, amino acid 385 is a histidine, and amino acid 388 is a leucine;
• the VP6 protein has greater than 95% identity to SEQ ID NO:
• 30, and wherein amino acid 101 is a valine;
• and
• the VP7 protein has greater than 95% identity to SEQ ID NO:
• 32;
• or
• b) the NSP1 protein has greater than 95% identity to SEQ ID NO:
• 72;
• the NSP2 protein has greater than 95% identity to SEQ ID NO:
• 78, and wherein amino acid 142 is a tyrosine;
• the NSP3 protein has greater than 95% identity to SEQ ID NO:
• 84;
• the NSP4 protein has greater than 95% identity to SEQ ID NO:
• 90;
• the NSP5 protein has greater than 95% identity to SEQ ID NO:
• 96, and wherein amino acid 60 is a valine;
• the VP1 protein has greater than 95% identity to SEQ ID NO:
• 102, and wherein amino acid 141 is a serine;
• the VP2 protein has with greater than 95% identity to SEQ ID NO:
• 10;
• the VP3 protein has greater than 95% identity to SEQ ID NO:
• 114, and wherein amino acid 365 is a serine;
• the VP4 protein has greater than 95% identity to SEQ ID NO:
• 120, and wherein amino acid 254 is a lysine, amino acid 367 is an alanine, amino acid 385 is an asparagine, and amino acid 392 is a glycine;
• the VP6 protein has greater than 95% identity to SEQ ID NO:
• 126, and wherein amino acid 101 is an alanine;
• and
• the VP7 protein has greater than 95% identity to SEQ ID NO:
• 132.